The use of chemotherapy resistance in cancer treatment

Cancer Journal from Scientific American

Volumn 3, Issue 2, 1997, Pages 60-69

  Deisseroth, Albert B ^a,b   Pizzorno, Giuseppe ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; CYTIDINE DEAMINASE; DIHYDROFOLATE REDUCTASE; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P;

CANCER CHEMOTHERAPY; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG UPTAKE; GENE TARGETING; GENE THERAPY; HUMAN; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVIEW;

ANIMALS; DRUG RESISTANCE, MULTIPLE; GENE THERAPY; GENES, MDR; HUMANS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; TUMOR CELLS, CULTURED;

EID: 0031002632     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Dunphy FR, Spitzer G, Buzdar AU et al. Treatment of estrogen receptor negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol 1990;8:1207-1216.
2. Peters WP. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of breast cancer: yes. Important Adv Oncol 1995;1:215-230.
3. Antman K, Ayash L, Elias A et al. A phase I study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992;10: 102-110.
4. Koc ON, Allay JA, Lee K et al. Transfer of drug resistance genes into hematopoietic progenitors to improve chemotherapy tolerance. Semin Oncol 1996;23:46-65.
5. Flasshove M, Banerjee D, Mineishi S et al. Ex vivo expansion and selection of human CD34+ peripheral blood progenitor cells after introduction of a mutated dihydrofolate reductase cDNA via retroviral gene transfer. Blood 1995;85:566-574.
6. Moreb J, Schweder M, Suresh A et al. Overexpression of the human aldehyde dehydrogenase class I results in increased resistance to 4-hydroxycyclophosphamide. Cancer Gene Therapy 1996;3: 24-31.
7. Laliberte J, Marquez V, Momparler AL. Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2-deoxycytidine by human cytidine deaminase. Cancer Chemother Pharmacol 1992; 30:7-11.
8. Greenbaum M, Letourneau S, Assar H et al. Retrovirus-mediated gene transfer of rat glutathione S-transferase Yc confers alkylating drug resistance in NIH 3T3 mouse fibroblasts. Cancer Res 1994; 54:3332-4447.
9. Pastan I, Gottesman M. Multiple-drug resistance in human cancer. N Engl J Med 1987;316:1388-1393.
10. Gottesman MM, Ambudkar SV, Ni B et al. Exploiting multidrug resistance to treat cancer. Cold Spring Harbor Symposium on Quantitative Biology 1994;59:677-683.
11. Sorrentino BP, Brandt SJ, Bodine D et al. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR-1. Science 1992;257:99-101.
12. Podda S, Ward M, Himelstein A et al. Transfer and expression of the human multiple drug resistance gene into live mice. Proc Natl Acad Sci USA 1992;89:9676-9680.
13. Hanania EG, Fu S, Roninson I et al. Resistance to Taxol chemotherapy produced in mouse marrow cells by safety-modified retroviruses containing a human MDR-1 transcription unit. Gene Therapy 1995;2:279-284.
14. Hanania E, Fu S, Zu Z et al. Chemotherapy resistance to Taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood cells with a retrovirus that contains the MDR-12 chemotherapy resistance gene. Gene Therapy 1995;2:285-294.
15. Hanania E, Deisseroth AB. Serial transplantation shows that early hematopoietic precursor cells are transduced by MDR-1 retroviral vector in a mouse gene therapy model. Cancer Gene Therapy 1994;1:21-25.
16. Cline MJ, Stang H, Mercola K et al. Gene transfer in intact animals. Nature 1980;204:422-445.
17. Nienhuis AW, Bunn JF, Turner PH et al. Expression of the human c-fms proto-oncogene in hematopoietic cells and its deletion in the 5q- syndrome. Cell 1985;42:421-428.
18. Ling V. P-glycoprotein, MDR-1 and tumor progression. Cancer Metastasis Rev 1994;13:223-233.
19. Chaudhary PM, Roninson I. Expression and activity of p-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1992;66:85-94.
20. Roninson IB. From amplification to function: the case of the MDR-1 genes. Muta Res 1992;276:151-161.
21. Chaudhary PM, Roninson IB. Induction of MDR-1 in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 1993;85:632-639.
22. Ueda K, Cardarelli C. Gottesman MM. Expression of a full-length cDNA for human "MDR-1" confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 1987; 84:3004-3008.
23. Sorrentino BP, McDonagh KT, Woods D et al. Expression of retroviral vectors containing the human multidrug resistance cDNA in hematopoietic cells transplanted mice. Blood 1995;86: 491-501.
24. Hesdorffer C, Amman K, Bank A et al. Human MDR gene transfer in patients with advanced cancer. Hum Gene Ther 1994;5: 1151-1160.
25. O'Shaughnessy JD, Cowan KH, Nienhuis AW et al. Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer. Hum Gene Ther 1994;5:891-911.
26. Deisseroth AB, Kavanagh J, Champlin R. Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of ovarian cancer: a pilot trial. Hum Gene Ther 1994;5:1507-1522.
27. Deisseroth AB, Holmes F, Hortobagyi G et al. Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of breast cancer: a pilot trial. Hum Gene Ther 1995;7: 401-416.
28. Gianni L, Munzone E, Capri G et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence finding study. J Clin Oncol 1995;13:2688-2700.
29. Hanania EG, Giles RE, Kavanagh J et al. Results of MDR-1 modification trial indicate that CFUGM do not contribute to post transplant hematopoietic recovery following intensive systemic therapy. Proc Natl Acad Sci, 1996, in press.
30. Huber BE, Richards CA, Krenitsky TA. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc Natl Acad Sci USA 1991; 88:8039-8043.
31. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase gene paradigm for a prospective cancer control strategy. Cancer Res 1986;46:5276-5281.
32. Culver KW, Ram Z, Walbridge S et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992;256:1550-1552.
33. Ram Z, Culver KW, Walbridge S. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res 1993; 53:83-88.
34. Freeman SM, Koeplin D, Abboud CN et al. The bystander effect: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993;53:5274-5284.
35. Colombo BM, Benedetti S, Ottolenghi S et al. The "bystander effect": association of U87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice. Hum Gene Ther 1995;6:763-772.
36. Bi LW, Parysek L, Warnick LM et al. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSVtk retroviral gene therapy. Hum Gene Ther 1993;4: 725-731.
37. Mesnil M, Piccoli C, Tiraby G et al. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA 1996;93:1831-1851.
38. Vile RG, Nelson JA, Catleden S et al. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 1994;54:6228-6234.
39. Gagandeep S, Brew R, Green B et al. Prodrug-activated gene therapy involvement of an immunological component in the bystander effect. Cancer Gene Therapy 1996;3:83-88.
40. Ramesh R, Marrogi AJ, Munshi A et al. In vivo analysis of the "bystander effect": a cytokine cascade. Exp Hematol 1996;24: 829-838.
41. Mullen CA, Kilstrup M, Blaese RM. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci USA 1992;89:33-37.
42. Pizzorno G, Cheng YC, Handschumacher RE. Pyrimidine and purine antimetabolites. In: Cancer Medicine (4th ed). Malvern, PA: Lea & Febiger, 1996;923-948.
43. Huber BE, Austin EA, Good VC et al. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res 1993;53: 4619-4626.
44. Domin BA, Mahony WB, Zimmerman TP. Transport of 5-fluorouracil and uracil into human erythrocytes. Biochem Pharmacol 1993;46:503-510.
45. Huber BE, Austin EA, Richards CA et al. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA 1994;91:8302-8306.
46. Trinh QT, Austin EA, Murray DM et al. Enzyme/prodrug gene therapy, comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res 1995;55:4808-4812.
47. Hirschowitz E, Ohwada A, Pascal W et al. In vivo adenovirus-mediated gene transfer of the E. coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Hum Gene Ther 1995;6:1055-1064.
48. Bridgewater JA, Springer CJ, Knox RJ et al. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur J Cancer 1995;31A:2362-2370.
49. Chen L, Waxman DJ, Chen D et al. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. Cancer Res 1996;56:1331-1340.
50. Marais R, Spooner RA, Light Y et al. Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. Cancer Res 1996;56:4735-4742.